Identifying knowledge gaps in the labeling of medications for geriatric patients.
Explore this paper's citation graph
Summary
With an expected doubling of the elderly population by 2040, it is time for pharmaceutical manufacturers to incorporate more robust prescribing information into their product labels of drugs used in older patients.
- Type
- article
- Published
- 2013-09-01
- Cited by
- 7
- References
- 8
- OpenAlex
- https://openalex.org/W304120758
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:21027311
Keywords
Medicine, Drug labeling, Population, Population ageing, Product (mathematics)
References
- Therapeutic experimentation in the elderly.
- Drug policy for an aging population--the European Medicines Agency's geriatric medicines strategy.
- Pediatric information in drug product labeling.
- Emergency hospitalizations for adverse drug events in older Americans.
- Off-Label Prescribing in Older Patients
- Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications.
- American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults
- The Census
Cited by
- Regulatory development of geriatric medicines: To GIP or not to GIP?
- Content Related to Older Adults in Canadian Innovator–Drug Product Monographs: An Exploratory Analysis
- Enrollment of older adults on oncology trials: An FDA perspective.
- Phase 1 Clinical Trials in the Elderly: Enrollment Challenges
- Older adult participation in cancer clinical trials: A systematic review of barriers and interventions
- Yaşlilarda Akilci İlaç Kullanimi
- A CROSS-SECTIONAL STUDY OF GERIATRIC LABELING FOR HIGH IMPACT MEDICATIONS USED BY OLDER AMERICANS
Related papers
No related papers recorded.